Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

Debating controversies in ALS 2:54
Debating controversies in ALS
Ettore Beghi
COVID-19: managing neurodegenerative diseases in southern Italy 6:13
COVID-19: managing neurodegenerative diseases in southern Italy
Giancarlo Logroscino
Potential environmental triggers of sporadic ALS 2:32
Potential environmental triggers of sporadic ALS
Peter Spencer
The reconstructed cohort design: tracking rare neurodegenerative diseases 4:40
The reconstructed cohort design: tracking rare neurodegenerative diseases
Giancarlo Logroscino
Potential toxins causing sporadic ALS: nitrosamines and hydrazines 2:40
Potential toxins causing sporadic ALS: nitrosamines and hydrazines
Peter Spencer
Identifying new therapeutic targets for neurodegenerative diseases 1:34
Identifying new therapeutic targets for neurodegenerative diseases
Bart De Strooper
Cycad toxins driving the ALS-Parkinsonism-Dementia complex 2:40
Cycad toxins driving the ALS-Parkinsonism-Dementia complex
Peter Spencer
ALS and FTD future research 1:51
ALS and FTD future research
Yuliya Shpilyukova
Genetics and ALS 0:48
Genetics and ALS
Rosario Vasta
ALS and FTD: current treatment landscape 1:40
ALS and FTD: current treatment landscape
Yuliya Shpilyukova
A new prognostic model for ALS 3:31
A new prognostic model for ALS
Rosario Vasta
C9orf72 hexanucleotide repeat expansion in ALS and FTD 2:31
C9orf72 hexanucleotide repeat expansion in ALS and FTD
Yuliya Shpilyukova
Plateaus in ALS progression 2:18
Plateaus in ALS progression
Rosario Vasta
The content of VJNeurology is intended for healthcare professionals